260 related articles for article (PubMed ID: 26341758)
1. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
[TBL] [Abstract][Full Text] [Related]
2. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
5. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
6. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
[TBL] [Abstract][Full Text] [Related]
8. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract][Full Text] [Related]
9. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
[TBL] [Abstract][Full Text] [Related]
10. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
[TBL] [Abstract][Full Text] [Related]
11. The Value of Anti-Müllerian Hormone in the Prediction of Spontaneous Pregnancy: A Systematic Review and Meta-Analysis.
Lin C; Jing M; Zhu W; Tu X; Chen Q; Wang X; Zheng Y; Zhang R
Front Endocrinol (Lausanne); 2021; 12():695157. PubMed ID: 34721287
[TBL] [Abstract][Full Text] [Related]
12. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
Wang SY; Wang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
[TBL] [Abstract][Full Text] [Related]
13. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
[TBL] [Abstract][Full Text] [Related]
14. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study.
Al-Rawi SA; Saleh BO; Al-Naqqash MA
Saudi Med J; 2018 Jul; 39(7):733-735. PubMed ID: 29968900
[TBL] [Abstract][Full Text] [Related]
16. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
Anderson RA; Su HI
Front Endocrinol (Lausanne); 2020; 11():574263. PubMed ID: 33117288
[TBL] [Abstract][Full Text] [Related]
18. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Lee DY; Park YH; Lee JE; Choi D
Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
[TBL] [Abstract][Full Text] [Related]
19. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.
Tremellen K; Zander-Fox D
Aust N Z J Obstet Gynaecol; 2015 Aug; 55(4):384-9. PubMed ID: 26230428
[TBL] [Abstract][Full Text] [Related]
20. Impact of breast cancer on anti-mullerian hormone levels in young women.
Su HI; Flatt SW; Natarajan L; DeMichele A; Steiner AZ
Breast Cancer Res Treat; 2013 Jan; 137(2):571-7. PubMed ID: 23224236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
